Results 131 to 140 of about 724,283 (165)

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

Digestive Diseases and Sciences, 2017
Background: CT-P13 is a biosimilar of Remicade©, an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD.
Angel Vilches-Arenas, Federico Argüelles-Arias   +1 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology

Immunotherapy, 2021
The drug infliximab has been a key milestone in the treatment of inflammatory conditions such as Crohn's disease, ulcerative colitis, rheumatoid arthritis and the seronegative spondyloarthritides. Biosimilar drugs followed the originator, further improving access and diversity of therapy choice.
Mai Ahmed, Giulia Bankov, Dan Casey, Martin Edward Perry   +3 more
openaire   +2 more sources

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Lancet, The, 2019
BACKGROUND: The infliximab biosimilar CT-P13 was approved for use in Crohn's disease after clinical comparison with originator infliximab in ankylosing spondylitis and rheumatoid arthritis; however, concerns about such indication extrapolation have been ...
HoUng Kim, Chang Soo Eun, Byong Duk Ye
exaly   +2 more sources

CT-P13 SC for the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology, 2021
Management of Rheumatoid Arthritis (RA) has improved following the implementation of early intensive treat to target recommendations and the availability of different biologicals. Most experience is with TNF blockers, but challenges remain in the efficacy/safety balance, immunogenicity, and long-term drug survival as well as availability and ...
openaire   +2 more sources

Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis

Journal of Clinical Gastroenterology, 2022
Background: We aimed to compare trough infliximab levels and the development of antidrug antibody (ADA) for 1 year between Crohn’s disease (CD) and ulcerative colitis (UC) patients who were biologic-naive, and to evaluate their impact on clinical outcomes.
Kim, Eun Soo, Kim, Sung Kook, Park, Dong Il, Kim, Hyo Jong, Lee, Yoo Jin, Koo, Ja Seol, Kim, Eun Sun, Yoon, Hyuk, Lee, Ji Hyun, Kim, Ji Won, Shin, Sung Jae, Kim, Hyung Wook, Kim, Hyun-Soo, Park, Young Sook, Kim, You Sun, Kim, Tae Oh, Lee, Jun, Choi, Chang Hwan, Han, Dong Soo, Chun, Jaeyoung, Kim, Hyun Soo   +20 more
openaire   +3 more sources

Ineffectiveness of infliximab CT‐P13 for the treatment of scleromyxedema: A case report

Dermatologic Therapy, 2017
a
Arginelli, Federica, Paganelli, Alessia, Rongioletti, Franco, Pellacani, Giovanni, Conti, Andrea   +4 more
openaire   +2 more sources

A Review of CT-P13: An Infliximab Biosimilar

BioDrugs, 2014
CT-P13 (Remsima™; Inflectra™), a biosimilar of reference infliximab (Remicade(®)), is approved by the European Medicines Agency for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis.
openaire   +2 more sources

CT-P13 in the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology, 2017
The first biosimilar infliximab, CT-P13 infliximab-dyyb was approved in 2013 by the European Medicines Agency (EMA) and in 2016 by the United States Food and Drug Administration (FDA) and has been used for the treatment of rheumatoid arthritis (RA) for 4 years.
openaire   +2 more sources

CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease

Expert Opinion on Biological Therapy, 2019
Introduction: CT-P13 was developed as an infliximab biosimilar in 2013. The primary structure of CT-P13 is identical to that of original infliximab and it has highly similar higher order structure, physiochemical characteristics, and biological properties.
Ahmad Albshesh, Shomron Ben-Horin
openaire   +2 more sources

Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis

Clinical and Experimental Rheumatology, 2021
Paediatric non-infectious uveitis (NIU) is an important cause of significant long-term complications and blindness in children. Infliximab (IFX) is a chimeric human/murine monoclonal antibody against TNF-α that is effective in NIU resistant to conventional therapies.
Betül, Sözeri, Esra, Kardeş, Enes, Salı, Deniz, Çakır, Ferhat, Demir   +4 more
openaire   +2 more sources